
CLVSQ
Healthcare · Biotechnology & Medical Research · $2.2M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 5, 2023 | Before the open | 0.00 | 0.00 | — |
| Mar 29, 2023 | Before the open | -0.37 | 0.00 | +100.0% |
| Nov 9, 2022 | Before the open | -0.41 | -0.39 | +4.9% |
| Aug 8, 2022 | Before the open | -0.41 | -0.50 | -22.0% |
| May 4, 2022 | Before the open | -0.43 | -0.44 | -2.3% |
| Feb 23, 2022 | Before the open | -0.57 | -0.48 | +15.8% |
| Nov 3, 2021 | Before the open | -0.48 | -0.56 | -16.7% |
| Aug 4, 2021 | Before the open | -0.56 | -0.61 | -8.9% |
| May 5, 2021 | Before the open | -0.72 | -0.64 | +11.1% |
| Feb 23, 2021 | Before the open | -0.77 | -1.02 | -32.5% |
| Nov 5, 2020 | Before the open | -0.99 | -0.89 | +10.1% |
| Aug 7, 2020 | Before the open | -1.04 | -1.15 | -10.6% |
| May 5, 2020 | After the close | -1.28 | -1.28 |
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant…
| 0.0% |
| Feb 24, 2020 | After the close | -1.71 | -1.81 | -5.8% |
| Nov 7, 2019 | Before the open | -1.89 | -1.78 | +5.8% |
| Aug 1, 2019 | Before the open | -1.71 | -2.27 | -32.7% |
| May 7, 2019 | Before the open | -1.74 | -1.63 | +6.3% |
| Feb 26, 2019 | Before the open | -1.72 | -1.88 | -9.3% |
| Oct 30, 2018 | After the close | -1.59 | -1.71 | -7.5% |
| Aug 1, 2018 | After the close | -1.88 | -1.94 | -3.2% |
| May 8, 2018 | After the close | -1.36 | -1.54 | -13.2% |
| Feb 26, 2018 | After the close | -1.30 | -1.04 | +20.0% |